A61K 31/4704
2-quinolinones
Official title: 2-Quinolinones, e.g. carbostyril
A61K31/4704 (2-quinolinones) appears on 355 US grants and 799 published applications in this corpus.
Search patents in A61K- Granted patents
- 355
- Published applications
- 799
- Assignees
- 344
- Inventors
- 1,510
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 6 | 0 |
| 2001 | 2 | 1 |
| 2002 | 8 | 6 |
| 2003 | 5 | 10 |
| 2004 | 3 | 9 |
| 2005 | 2 | 11 |
| 2006 | 7 | 18 |
| 2007 | 0 | 23 |
| 2008 | 1 | 16 |
| 2009 | 8 | 18 |
| 2010 | 4 | 32 |
| 2011 | 6 | 27 |
| 2012 | 13 | 24 |
| 2013 | 17 | 45 |
| 2014 | 28 | 50 |
| 2015 | 24 | 65 |
| 2016 | 24 | 61 |
| 2017 | 19 | 68 |
| 2018 | 18 | 40 |
| 2019 | 17 | 30 |
| 2020 | 20 | 36 |
| 2021 | 27 | 44 |
| 2022 | 17 | 40 |
| 2023 | 20 | 33 |
| 2024 | 14 | 36 |
| 2025 | 22 | 34 |
| 2026 | 11 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Assisted loading of hydrophobic molecules into liposomes6 Oct 2026US 12,751,922 B2University of Connecticut
- Rebamipide for use in prevention and/or treatment of arterial stiffness29 Sep 2026US 12,746,233 B2Square Power Ltd.
- S100 proteins as novel therapeutic targets in myeloproliferative neoplasms22 Sep 2026US 12,740,977 B2Erasmus University Medical Center Rotterdam
- Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors21 Jul 2026US 12,685,719 B2University of Tennessee Research Foundation
- Compositions and methods for combinatorial drug discovery in nanoliter droplets7 Jul 2026US 12,673,084 B2Massachusetts Institute of Technology
- Compositions and methods for reducing adverse side effects in cancer treatment20 Aug 2026US 2026/0240810 A1EpicentRx, Inc.
- Use of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) in Rare Anemia13 Aug 2026US 2026/0234146 A1Kind Pharmaceutical
- Methods of treating cardiometabolic diseases6 Aug 2026US 2026/0226023 A1
- Use of long-acting ß2ar agonist in preparation of drugs for treating cancers30 Jul 2026US 2026/0216103 A1Hong Kong Sxmeterol Pharmaceutical Co., Limited
- Long-acting oral pharmaceutical comprising hypoxia-inducible factor prolyl hydrolase inhibitor and use thereof16 Jul 2026US 2026/0199305 A1Kind Pharmaceutical
Most cited
By later US patents
- Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction140US 6,037,346 AVivus, Inc. · 2000
- Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction85US 6,127,363 AVivus, Inc. · 2000
- Treatment for multiple sclerosis82US 8,399,514 B2Biogen Idec MA Inc. · 2013
- Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation68US 6,403,597 B1Vivus, Inc. · 2002
- Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction67US 6,156,753 AVivus, Inc. · 2000